Immunoglobulin G1 [de-C-terminal-lysine], anti-(human blood-coagulation factor III) (human monoclonal XB002 ?1-chain), disulfide with human monoclonal XB002 ?-chain, dimer, reduced, tetrakis(thioether) with N-[3-[2-[2-[2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)ethoxy]ethoxy]ethoxy]-1-oxopropyl]-L-valyl-N5-(aminocarbonyl)-N-[4-[[[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[(N,N-dimethyl-L-valyl-L-valyl)methylamino]-3-methoxy-5-methyl-1-oxoheptyl]-2-pyrrolidinyl]-3-methoxy-2-methyl-1-oxopropyl]amino]sulfonyl]phenyl]-L-ornithinamide
Triple Negative Breast Cancer
Exelixisantibody_drug_conjugatePhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 65/ 100
Competitive context
448 Active assets in the Triple Negative Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capivasertib AstraZeneca | Phase 3 | BB |
Cyclophosphamide M.D. Anderson Cancer Center | Phase 4 | BB |
Carboplatin M.D. Anderson Cancer Center | Phase 4 | BB |
Veliparib National Cancer Institute (NCI) | Phase 3 | BB |
Atezolizumab European Institute of Oncology | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Immunoglobulin G1 [de-C-terminal-lysine], anti-(human blood-coagulation factor III) (human monoclonal XB002 ?1-chain), disulfide with human monoclonal XB002 ?-chain, dimer, reduced, tetrakis(thioether) with N-[3-[2-[2-[2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)ethoxy]ethoxy]ethoxy]-1-oxopropyl]-L-valyl-N5-(aminocarbonyl)-N-[4-[[[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[(N,N-dimethyl-L-valyl-L-valyl)methylamino]-3-methoxy-5-methyl-1-oxoheptyl]-2-pyrrolidinyl]-3-methoxy-2-methyl-1-oxopropyl]amino]sulfonyl]phenyl]-L-ornithinamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →